{
    "Trade/Device Name(s)": [
        "HemosIL RecombiPlasTin 2G"
    ],
    "Submitter Information": "Instrumentation Laboratory Company",
    "510(k) Number": "K070005",
    "Predicate Device Reference 510(k) Number(s)": [
        "K043184"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GJS",
        "GIS"
    ],
    "Summary Letter Date": "August 15, 2007",
    "Summary Letter Received Date": "March 23, 2007",
    "Submission Date": "March 22, 2007",
    "Regulation Number(s)": [
        "21 CFR 864.7750",
        "21 CFR 864.7340"
    ],
    "Regulation Name(s)": [
        "Prothrombin Time Test",
        "Fibrinogen Determination System"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Prothrombin Time (PT)",
        "Fibrinogen"
    ],
    "Specimen Type(s)": [
        "Human citrated plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "IL Coagulation Systems",
        "ELECTRA Systems",
        "ACL Family",
        "ACL Futura",
        "ACL Advance",
        "ACL TOP",
        "ACL 6000",
        "ACL 10000",
        "ELECTRA 1600C"
    ],
    "Method(s)/Technology(ies)": [
        "PT-based assay",
        "Clotting time measurement"
    ],
    "Methodologies": [
        "Quantitative in vitro diagnostic determination"
    ],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL RecombiPlasTin 2G, a thromboplastin reagent for PT and Fibrinogen testing on IL Coagulation Systems",
    "Indications for Use Summary": "High sensitivity thromboplastin reagent for quantitative in vitro diagnostic determination of Prothrombin Time (PT) and Fibrinogen in human citrated plasma for evaluation of the extrinsic coagulation pathway and monitoring of oral anticoagulant therapy",
    "fda_folder": "Hematology"
}